Impact of self-financed rotavirus vaccines on hospital stays and costs in Spain after a 3-year introductory period.

ABSTRACT: Vaccination has reduced rotavirus hospitalizations by 25% in European regions with low-moderate vaccine availability. We aimed to quantify the reduction in hospital costs after the longest period in which Rotarix® and Rotateq® were simultaneously commercially available in Spain. Cases, length of stay (LOS), and diagnosis-related groups (DRGs) were retrieved from the Minimum Basic Data Set. Healthcare expenditure was estimated through the cost accounting system Gescot®. DRGs were clustered: I, non-bacterial gastroenteritis with complications; II, without complications; III, requiring surgical/other procedures or neonatal cases (highest DRG weights). Comparisons between pre (2003-2005)- and post-vaccine (2007-2009) hospital stays and costs by DRG group were made. Rotaviruses were the most co

SUBMITTER: Redondo-Gonzalez O 

PROVIDER: S-EPMC9203311 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature